Literature DB >> 24735893

Intraoperative ultrasound in conservative surgery for non-palpable breast cancer after neoadjuvant chemotherapy.

M Ramos1, J C Díez2, T Ramos3, R Ruano4, M Sancho5, J M González-Orús3.   

Abstract

AIMS: A complete clinical response after neoadjuvant chemotherapy (NACT) in breast cancer patients hinders the localization of the residual lesion and the removal of a minimum amount of breast tissue. The aim of the present work is to report our single-centre experience with intraoperative ultrasound-guided (IOUS) excision performed by surgeons in these patients. PATIENTS AND METHODS: From January 2008 to December 2012, IOUS excisions were performed on 58 patients with a previous intralesional ultrasound-detectable metallic marker and non-palpable breast cancer after NACT. The specimen margins were estimated by ultrasonography and macroscopic pathologic examination. Successful lesion removal, specimen weight, and analysis of the results as regards margins were evaluated, and the need for breast-conserving re-excision and mastectomy was considered.
RESULTS: After NACT the average ultrasound/mammography and MRI diameters were 11.7 mm (0-30) and 9.1 mm (0-40) respectively. In all cases, the residual lesion or tissue around the marker was removed. The average weight of the specimens was 26.4 g (6-84), being lower in cases of complete response according to ultrasound (p < 0.05). In 4 patients (6.8%), breast-conserving re-excision was carried out, and in 3 patients (5.2%) a secondary mastectomy was performed, two of which had invasive lobular carcinoma.
CONCLUSIONS: The emplacement of a readily echodetectable metal marker before NACT makes IOUS excision feasible in an increasing number of complete clinical responses, with the excision of small amounts of breast tissue and a high percentage of conservative breast surgery. This technique requires surgeons to be trained, but has the advantage of a reduced use of other hospital services, better planning of operating theatres, and less discomfort for patients, which means that it is attractive and indeed recommendable.
Copyright © 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Complete clinical response; Intraoperative ultrasound localization; Neoadjuvant chemotherapy; Non-palpable; Re-excision rate

Mesh:

Year:  2014        PMID: 24735893     DOI: 10.1016/j.ijsu.2014.04.003

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  7 in total

Review 1.  Surgical Management of Breast Cancer Treated with Neoadjuvant Therapy.

Authors:  Octavi Cordoba; Lourdes Carrillo-Guivernau; Carmen Reyero-Fernández
Journal:  Breast Care (Basel)       Date:  2018-07-25       Impact factor: 2.860

2.  Hygroscopic sonographically detectable clips form characteristic breast and lymph node pseudocysts.

Authors:  Moshe Carmon; Sofia Zilber; David Gekhtman; Oded Olsha; Tal Hadar; Eliahu Golomb
Journal:  Mod Pathol       Date:  2017-08-11       Impact factor: 7.842

Review 3.  Does Tumor Marking Before Neoadjuvant Chemotherapy Helps Achieve Better Outcomes in Patients Undergoing Breast Conservative Surgery? A Systematic Review.

Authors:  Chandan Kumar Jha; Goonj Johri; Prashant Kumar Singh; Sanjay Kumar Yadav; Upasna Sinha
Journal:  Indian J Surg Oncol       Date:  2021-08-03

4.  First Reported Use of the Faxitron LOCalizer™ Radiofrequency Identification (RFID) System in Europe - A Feasibility Trial, Surgical Guide and Review for Non-palpable Breast Lesions.

Authors:  Wolfram Malter; Johannes Holtschmidt; Fabinshy Thangarajah; Peter Mallmann; Barbara Krug; Mathias Warm; Christian Eichler
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 5.  Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.

Authors:  Kowsi Murugappan; Apoorva Saboo; Lu Kuo; Owen Ung
Journal:  Gland Surg       Date:  2018-12

6.  Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Authors:  José H Volders; Vera L Negenborn; Pauline E Spronk; Nicole M A Krekel; Linda J Schoonmade; Sybren Meijer; Isabel T Rubio; M Petrousjka van den Tol
Journal:  Breast Cancer Res Treat       Date:  2017-12-06       Impact factor: 4.872

7.  Novel Multimodal, Multiscale Imaging System with Augmented Reality.

Authors:  Christopher Mela; Francis Papay; Yang Liu
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.